Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study evaluates survival and relapse outcomes of total body irradiation versus chemotherapy conditioning regimens in haploidentical hematopoietic cell transplantation for adult AML patients in first remission, revealing no clear surviv
Low-level FLT3-ITD microclones, detected via NGS in young adults with AML, independently increase relapse risk comparable to macroclones, challenging current risk stratification and underscoring the need to integrate advanced genetic testin
This review synthesizes evidence on the role of RNA-binding protein G3BP2 in conferring venetoclax resistance in AML through stabilizing ELF1 mRNA and upregulating MCL1 transcription, highlighting novel therapeutic avenues combining G3BP2 i
In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA reg
This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isofo
This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.
Single-cell multiomic analysis reveals how genotype-immunophenotype relationships shape clonal evolution in NPM1-mutated acute myeloid leukemia, highlighting implications for prognosis and therapy response.
Dual inhibition of CDK2 and CDK4/6 demonstrates synergistic anti-leukemic effects in AML by suppressing the Rb/E2F axis, offering a promising therapeutic strategy to improve outcomes in this challenging hematologic malignancy.
A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
Researchers have identified oncofetal chondroitin sulfate (ofCS) as a novel target for antibody-drug conjugates in AML. Unlike traditional targets, ofCS is absent in healthy tissues, potentially reducing hematotoxicity and expanding treatme
This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
In the randomized, double‑blind phase II QUIWI trial, adding quizartinib to standard induction/consolidation chemotherapy and single‑agent maintenance significantly improved event‑free survival and overall survival for adults 18–70 years wi
Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre
In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc
Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.
Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a
A phase 2 trial demonstrates that oral decitabine and cedazuridine maintenance following hematopoietic stem-cell transplantation may improve disease-free survival in very high-risk AML and MDS patients with manageable safety.
Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against app